UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

May 11, 2023

Treatment with trastuzumab deruxtecan resulted in lower exposure-adjusted incidence rates per patient-year of treatment-emergent adverse effects compared with treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer, according to safety analysis from the phase 3 DESTINY-Breast04 trial.

April 26, 2023

Rahul Aggarwal, MD, discusses key findings from a phase 2a trial evaluating the combination of BXCL701 and pembrolizumab in patients with metastatic castration-resistant prostate cancer with the small cell neuroendocrine cancer phenotype.

April 24, 2023

Dr Friedlander discusses the FDA approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma, key efficacy and safety data from the EV-103 trial, and the importance of incorporating this regimen into the frontline setting for this population.

April 13, 2023

Terence Friedlander, MD, discusses the significance of the FDA approval of enfortumab vedotin combined with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, and expands on the data from the EV-103/KEYNOTE-869 trial that supported the approval.

April 10, 2023

The combination of BXCL701 and pembrolizumab produced durable responses in patients with platinum-resistant small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer, according to data from a phase 2a trial presented at the 2023 Genitourinary Cancers Symposium.

April 03, 2023

Terence Friedlander, MD, discusses the significance of the FDA approval of frontline enfortumab vedotin combined with pembrolizumab in patients with urothelial carcinoma.

March 30, 2023

Laura J. Esserman, MD, MBA, discusses the effect early end points could have for clinical trials in breast cancer, how these end points could help usher in more individually tailored treatment options based on an individual patient’s disease and response, and how early end points have been used in the ongoing phase 2 I-SPY 2 trial.

March 27, 2023

Faculty from the 40th Annual Miami Breast Cancer Conference® feature updates in the treatment of patients across the breast cancer continuum.

March 07, 2023

As more antibody-drug conjugates emerge and investigators foresee fam-trastuzumab deruxtecan-nxki moving forward in lines of treatment for metastatic disease, the treatment landscape of hormone receptor–positive, HER2-negative breast cancer continues to expand and shift.

March 03, 2023

Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.

February 23, 2023

Closing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.

February 23, 2023

Experts Amod Sarnaik, MD, and Krishna Komanduri, MD, consider lessons learned about TILs and CAR T-cell therapy in hematologic cancers, and how they anticipate TILs fitting into treatment paradigms for solid tumors.

February 16, 2023

Shared insight from Amod Sarnaik, MD, and Krishna Komanduri, MD, on the halted DELTA-1 clinical trial of ITIL-168 in melanoma, followed by a focused discussion of SITC 2022 data on emerging TIL design and manufacturing strategies.

February 16, 2023

Expert perspectives on results from C-144-01, which utilized the TIL therapy lifileucel in the setting of metastatic melanoma, and situations in which the regimen might be used in clinical practice.

February 09, 2023

A focused discussion on clinical trial data presented at SITC 2022 elucidating the biologic activity of tumor-infiltrating lymphocyte therapies.

February 02, 2023

Shared insight on the benefits and drawbacks of using tumor-infiltrating lymphocyte therapy for treatment of solid tumors, as compared to chimeric antigen receptor (CAR) T-cell therapy.

February 02, 2023

Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address existing unmet needs in the treatment of solid tumors, including melanoma and non–small cell lung cancer.

December 28, 2022

An unshakeable belief in the power of the immune system and a deep-seated desire to make the world a better place have guided Eric J. Small, MD, throughout his career.

December 26, 2022

Dr Rugo discusses overall survival in the TROPiCS-02 trial, post-progression treatments after ribociclib and endocrine therapy in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies, and what the AMALEE trial indicates about optimal doses of ribociclib in hormone receptor–positive breast cancer.

November 09, 2022

Hope Rugo, MD, discusses the challenges of differentiating between HER2-low and HER2-negative metastatic breast cancer and prognostic differences in HER2+ and HER2-low metastatic breast cancer.